Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Secondary Prevention of Coronary Artery Disease

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • KeyboardArrowRight

    Overview and Recommendations

    • Background

    • Evaluation

    • Management

  • Related Summaries

  • Description

  • Overview

  • KeyboardArrowRight

    Cardiac Rehabilitation

    • Recommendations (cardiac rehabilitation)

    • KeyboardArrowRight

      Efficacy (cardiac rehabilitation)

    • Disease management and secondary prevention programs

  • KeyboardArrowRight

    Diet

    • Recommendations for secondary prevention

    • Evidence (diet)

    • Omega-3 fatty acids

    • Moderate alcohol consumption

  • KeyboardArrowRight

    Physical Activity

    • Recommendations for secondary prevention

    • Evidence (physical activity)

    • Sexual activity

  • Weight

  • KeyboardArrowRight

    Smoking Cessation

    • Related summaries for smoking cessation

    • Recommendations for smoking cessation

    • Evidence for smoking cessation

  • Medication Adherence

  • KeyboardArrowRight

    Antihypertensive Therapies

    • KeyboardArrowRight

      Blood pressure

      • KeyboardArrowRight

        Target blood pressure (evidence)

    • KeyboardArrowRight

      Renin-angiotensin-aldosterone system inhibitors

      • KeyboardArrowRight

        Angiotensin converting enzyme (ACE) inhibitors

        • Recommendations (ACE inhibitors)

        • Efficacy (ACE inhibitors)

        • Individual ACE inhibitor trials

        • Adverse effects and precautions (ACE inhibitors)

      • KeyboardArrowRight

        Angiotensin receptor blockers (ARBs)

        • Recommendations (ARBs)

        • Comparative efficacy

        • Combination ACE inhibitors plus ARBs

      • Aldosterone blockade

      • Renin inhibitor

    • KeyboardArrowRight

      Beta blockers

      • Recommendations (beta blockers)

      • KeyboardArrowRight

        Efficacy (beta blockers)

      • Adverse effects and precautions (beta blockers)

    • KeyboardArrowRight

      Calcium channel blockers

      • Recommendations (calcium channel blockers)

      • Efficacy (calcium channel blockers)

  • KeyboardArrowRight

    Lipids

    • Recommendations for statins for secondary prevention from professional organizations

    • KeyboardArrowRight

      Statins

      • Efficacy (statins for secondary prevention)

      • Comparative efficacy of statins

    • PCSK9 inhibitors

    • Fibrates

    • Other medications

  • Antiplatelets and Anticoagulants

  • KeyboardArrowRight

    Diabetes Management

    • Recommendations

    • Glucose-lowering medications

  • Influenza Vaccination

  • Monoclonal antibodies

  • KeyboardArrowRight

    Interventions that are Ineffective or Not Well Studied

    • Omega-3 fatty acids

    • Niacin

    • Vitamins

    • Hormone replacement therapy

    • Colchicine

    • Methotrexate

    • Other cardiovascular medications

    • Periodontal therapy

    • Chelation therapy

    • KeyboardArrowRight

      Other alternative treatments

      • L-arginine

      • Creatine supplementation

  • KeyboardArrowRight

    Quality Improvement

    • Physician Quality Reporting System Quality Measures

    • Quality and Outcomes Framework Indicators

    • Quality improvement evidence

  • KeyboardArrowRight

    Guidelines and Resources

    • KeyboardArrowRight

      Guidelines

      • United States guidelines

      • United Kingdom guidelines

      • Canadian guidelines

      • European guidelines

      • Australian and New Zealand guidelines

  • Patient Information

  • KeyboardArrowRight

    References

    • General references used

    • Recommendation grading systems used

    • Synthesized Recommendation Grading System for DynaMed

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Topic Editor
Maria Sciammarella MD
KeyboardArrowDown
Affiliations

Associate Clinical Professor, University of California, San Francisco; California, United States

Conflicts of Interest

Dr. Sciammarella declares no relevant financial conflicts of interest.

Recommendations Editor
Esther Jolanda van Zuuren MD
KeyboardArrowDown
Affiliations

Head of Allergy, Dermatology, and Venereology, Leiden University Medical Centre; Netherlands

Conflicts of Interest

Dr. van Zuuren declares no relevant financial conflicts of interest.

Deputy Editor
Peter Oettgen MD
KeyboardArrowDown
Affiliations

Editor in Chief, DynaMed; Cardiologist, Beth Israel Deaconess Medical Center; Massachusetts, United States; Associate Professor of Medicine, Harvard Medical School; Massachusetts, United States

Conflicts of Interest

Dr. Oettgen declares no relevant financial conflicts of interest.

CheckCircle

top